Medicines & supplements – Current GIS Alerts 2026
Found 791 alerts in the Medicines & supplements category. Check batch numbers, shops, and hazard information.
Common hazards in this category
All recalled products
Clatra
The product does not meet quality requirements due to a negative test result for contamination with particles visible to the naked eye, which in sterile eye drops may pose a risk to the patient’s eye. Potential effects: eye irritation, mechanical damage, infection, ophthalmic complications.
Acurenal
suspected non-compliance with the specification for the parameter "impurity A content" in stability studies, including an OOS result for batch 80212781; after limit extension and toxicological assessment, no risk to the patient was confirmed. Potential effects: no or minimal health risk; the product remains effective.
Acurenal
In stability testing for the “impurity A content” parameter, an out-of-specification (OOS) result was obtained relative to the original specification, requiring a change of the limit in the product quality specification, although it was assessed not to pose a risk to patients. Potential effects: no significant health effects; the product remains effective and safe.
Angeliq
The medicinal product was released to the market with an outdated version of the patient leaflet; a health risk cannot be excluded due to information inconsistent with the approved documentation. Potential effects: incorrect use of the drug, lack of treatment efficacy, complications or increased adverse reactions.
Angeliq
It was found that an outdated version of the patient leaflet was included with batch KT0SLCS, so information on use, safety and adverse reactions does not meet current requirements. Potential effects: improper use of the medicine, lack of efficacy, increased risk of adverse reactions or complications.
Triacyt MR
The identified non-conformity involving an incorrect leaflet lacking updated information on severe cutaneous adverse reactions may affect the safe use of the medicine. Potential effects: misuse of the medicine, severe skin reactions, complications.
Triacyt MR
The incorrect leaflet attached to batch 250202 does not contain updated information on the possibility of severe cutaneous adverse reactions during trimetazidine dihydrochloride use, which may affect treatment safety. Potential effects: severe skin reactions, complications, improper use of the medicine.
Axonalgin
The product does not meet the requirements for chromatographic purity of metamizole sodium monohydrate: a single unspecified impurity and impurity E are present, exceeding the accepted specification. Potential effects: unpredictable adverse reactions, possible toxic effects or reduced efficacy of the medicine.
Kwas traneksamowy Tillomed
The product does not meet quality requirements due to contamination with particles visible to the naked eye; in batch TR0232405A particles were found in the solution for injection. Potential effects: embolism, vascular inflammation, local post‑injection complications.
Furaginum MAX US Pharmacia
The product does not meet established quality requirements for the nitrosamine NDMA content parameter, indicating possible contamination with this compound, which has potential carcinogenic effects. Potential effects: possible toxicity and increased risk of carcinogenic effects.
Elenium
The identified non-compliance in the active substance release parameter affects the quality of the medicine and may impact its efficacy and safety; a health risk from keeping the defective batches on the market cannot be excluded. Potential effects: lack of therapeutic effect, disease complications.
Elenium
The detected non-compliance in the dissolution of the active substance affects product quality and may impact the effectiveness and safety of its use; a risk to human health cannot be excluded. Potential effects: lack of therapeutic effect, complications.
Elenium
The identified non-compliance in the parameter of active substance release affects the product’s quality and may impact its effectiveness and safety of use. The acceptance criterion for the minimum amount of released active substance was not met. Potential effects: possible lack of treatment efficacy and related disease complications.
Elenium
A non-compliance was found in the parameter of the degree of active substance release, which affects product quality and may impact the effectiveness and safety of its use; a risk to human health cannot be excluded. Potential effects: lack of treatment efficacy, worsening of symptoms, unpredictable drug action.
Elenium
The identified non-compliance in the active substance release rate affects the product’s quality and may impact its efficacy and safety. The acceptance criterion for the minimum amount of released active substance was not met. Potential effects: lack of treatment efficacy, deterioration of health, complications related to insufficient drug action.
Elenium
The identified non‑compliance in the active substance dissolution parameter affects product quality and may impact the effectiveness and safety of its use; a risk to human health cannot be excluded. Potential effects: lack of therapeutic effect, adverse reactions, health risk.
Enema
Cloudiness and opalescence of the solution caused by micro sediment originating from the active substance (trace amounts of titanium compounds in the solution); initially suspected quality defect of the medicinal product. Potential effects: possible irritation of the rectal mucosa or reduced treatment efficacy.
Soliris
Risk of confusion among medical staff due to information on the route and method of administration being given in Slovak and Czech on the vial. Potencjalne skutki: incorrect administration of the drug, treatment complications, risk to patient health.
Soliris
Incorrect vial labeling was found – the phrases “concentrate for solution for infusion”, “for intravenous use”, “dilute before use” were in Slovak and Czech, which may hinder correct administration and a risk to health cannot be excluded. Potential effects: serious administration errors, lack of efficacy or treatment complications.
Bupivacaine and Epinephrine, Bupivacaine-Epinephrine 0,5%,
The product is a solution for injection; a change in colour from clear to opalescent, brown or yellow may indicate drug degradation; a discoloured product must not be used and must be discarded. Potential effects: lack of efficacy, adverse reactions or complications after administration of a solution of inadequate quality.
What to do if you bought a recalled product?
If you have purchased any of the products listed above, stop using or consuming them immediately. You can return the product to the store where you bought it for a full refund. Keep the receipt if possible, but most stores will accept returns even without one.